Small Molecules

26 Jun 2020 FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
26 Jun 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
26 Jun 2020 AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
25 Jun 2020 Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
25 Jun 2020 Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial
25 Jun 2020 Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
24 Jun 2020 ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
24 Jun 2020 IM Therapeutics Announces First Patient Dosed in Phase 1 Study of Its Lead Drug IMT-002 for Type 1 Diabetes
24 Jun 2020 Sun Pharma Announces Pre-Clinical Data on GL0034, an Experimental NCE to Treat Type 2 Diabetes and Obesity
23 Jun 2020 Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
23 Jun 2020 Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program
23 Jun 2020 Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries
23 Jun 2020 ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA
23 Jun 2020 Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19
23 Jun 2020 Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
22 Jun 2020 RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
22 Jun 2020 Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway
20 Jun 2020 Phase-3 Clinical Trial of MT-7117 INITIATED IN THE U.S. for Rare DiseaseS, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
20 Jun 2020 Reistone Announces First Patient Dosed in a Phase II Global Study of SHR0302 JAK Inhibitor for Alopecia Areata
20 Jun 2020 Terns Pharmaceuticals Initiates the LIFT Study, a Phase 2a Clinical Trial of TERN-101 for the Treatment of NASH
19 Jun 2020 Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
18 Jun 2020 RINVOQ™ (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
18 Jun 2020 Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment
17 Jun 2020 TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
17 Jun 2020 Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up